Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 14/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173785 | 0.82 | SLC6A9 (0.42) | TMEM97SIGMAR1SLC6A9KCNH2 | |
| SCHEMBL20178672 | 0.76 | SLC6A9 (0.38) | SLC6A9KCNH2 | |
| SCHEMBL20178630 | 0.74 | SLC6A9 (0.40) | SLC6A9KCNH2 | |
| SCHEMBL20178677 | 0.71 | UBE2M (0.35) | TMEM97SIGMAR1KCNH2ACHEUBE2M | |
| SCHEMBL20178662 | 0.71 | TRPV4 (0.38) | SLC6A9 | |
| SCHEMBL20307155 | 0.67 | MEN1 (0.59) | TMEM97SIGMAR1KCNH2 | |
| SCHEMBL4821952 | 0.63 | SLC6A9 (0.42) | SLC6A9KCNH2 | |
| SCHEMBL3872838 | 0.63 | SLC6A9 (0.35) | SLC6A9 | |
| SCHEMBL21725507 | 0.63 | IDH1 (0.31) | — | |
| SCHEMBL30488188 | 0.63 | KDM4E (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | TMEM97 192/4885SIGMAR1 397/4885SLC6A9 559/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | TMEM97 192/4885SIGMAR1 397/4885SLC6A9 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.